Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ADXN | 6-K | bearish | 7/10 | Addex Therapeutics reported H1 2026 financial results showing a net loss of CHF 3.5 million (vs CHF 3.3 million in H1 20 | Sep 28, 2026 |
| MBRX | 8-K | bullish | 5/10 | Moleculin Biotech announced the publication of a peer-reviewed pooled analysis of Annamycin's cardiac safety in Frontier | Sep 28, 2026 |
| JAGX | 8-K | bearish | 6/10 | Jaguar Health entered into exchange agreements with Streeterville Capital to issue 481,584 shares of common stock in exc | Sep 28, 2026 |
| DMRA | INSIDER-BUY | bullish | 5/10 | Damora Therapeutics CEO Jarrett Jennifer made a single open-market purchase of 12,500 shares for $253K at $20.23/share o | Sep 28, 2026 |
| TLSA | 6-K | neutral | 4/10 | Tiziana Life Sciences announced that the first three participants have been dosed in the Phase 2a Healey ALS MyMatch BAN | Sep 28, 2026 |
| PBM | 6-K | neutral | 4/10 | Psyence Biomedical's wholly-owned Texas subsidiary, TIRC, entered a binding term sheet with PsyLabs for exclusive U.S. r | Sep 28, 2026 |
| PBM | PRESS-RELEASE | neutral | 4/10 | Psyence Biomedical subsidiary Texas Ibogaine Research Corporation (TIRC) signed a binding term sheet with related-party | Sep 28, 2026 |
| BLSM | PRESS-RELEASE | bearish | 7/10 | BlossomHill Therapeutics reported Q2 2026 EPS of -$8.75, a 874% miss vs consensus of -$0.90, with zero revenue. The comp | Sep 28, 2026 |
| PRFX | 6-K | bullish | 7/10 | PRF Technologies disclosed receipt of an activist demand from S.H.N. Financial Investments Ltd., which holds ~5.7% of vo | Sep 28, 2026 |
| HEPA | 8-K | bearish | 6/10 | Hepion Pharmaceuticals dismissed its auditor, Grassi & Co., and engaged Rosenberg Rich Baker Berman P.A. as its new inde | Sep 28, 2026 |
| CELU | 8-K | bearish | 7/10 | Celularity entered into a securities purchase agreement for up to $25M in senior secured convertible notes and warrants, | Sep 28, 2026 |
| MNOV | PRESS-RELEASE | mixed | 5/10 | MediciNova reported Phase 2 topline results for MN-001 (tipelukast) in hypertriglyceridemia and NAFLD with T2DM. The stu | Sep 28, 2026 |
| ZYME | PRESS-RELEASE | bullish | 7/10 | Zymeworks completed its acquisition of Theravance Biopharma, adding YUPELRI (revefenacin) for a mid-teens base-case IRR. | Sep 28, 2026 |
| PULM | EFFECT | bearish | 5/10 | The SEC declared effective Pulmatrix's S-4 registration statement (File No. 333-297342) on September 25, 2026, clearing | Sep 28, 2026 |
| QNRX | EFFECT | bearish | 6/10 | The SEC declared effective Quoin Pharmaceuticals' S-3 registration statement (File No. 333-299021) on September 25, 2026 | Sep 28, 2026 |
| CYTK | CLUSTER | bearish | 5/10 | Two CYTK insiders, including the CEO and EVP of R&D, sold a combined $730K in open-market sales over a one-week window. | Sep 27, 2026 |
| ARCT | COURT-RULING | neutral | 2/10 | A federal district court issued a case management order in Arcturus's trade secret litigation against AbbVie/Capstan, re | Sep 27, 2026 |
| MRK | COURT-RULING | neutral | 1/10 | This is a routine procedural order granting pro hac vice admission for an attorney in the ongoing Kaiser Foundation Heal | Sep 27, 2026 |
| SPRY | COURT-RULING | neutral | 3/10 | A federal district court denied ARS Pharmaceuticals' motion to dismiss a former employee's Title VII gender discriminati | Sep 27, 2026 |
| ABBV | COURT-RULING | neutral | 2/10 | A federal district court issued a routine case management order in a trade secret dispute between Arcturus Therapeutics | Sep 27, 2026 |
| ADRX | 424B4 | bullish | 7/10 | ADARx Pharmaceuticals priced its initial public offering of 26,250,000 shares at $17.00 per share, raising $446.25 milli | Sep 25, 2026 |
| BAK | 6-K | bearish | 7/10 | Braskem filed a 6-K responding to a B3 inquiry about media reports that the São Paulo State Public Prosecutor's Office ( | Sep 25, 2026 |
| CYPH | CLUSTER | bearish | 4/10 | Two directors of CYPHERPUNK TECHNOLOGIES INC. sold a combined $855K in open-market sales over a one-week window, represe | Sep 25, 2026 |
| AKAN | 6-K | bearish | 7/10 | Akanda Corp. announced it is abandoning all cannabis cultivation and related businesses, including its option to purchas | Sep 25, 2026 |
| DYAI | 8-K | bearish | 7/10 | Dyadic International received two Nasdaq deficiency notices on September 25, 2026: one for failing to maintain the minim | Sep 25, 2026 |
| CLDI | 8-K | bearish | 7/10 | Calidi Biotherapeutics received a delisting notice from NYSE American on September 21, 2026, for failing to meet the $4. | Sep 25, 2026 |
| ETRA | SC 13D | neutral | 5/10 | OrbiMed Advisors, a healthcare-focused investment firm, filed a Schedule 13D disclosing beneficial ownership of 6,885,17 | Sep 25, 2026 |
| CYDY | S-3 | bearish | 7/10 | CytoDyn filed an S-3 registration statement to register 794,972,289 shares of common stock for resale by selling stockho | Sep 25, 2026 |
| INBP | 8-K | bearish | 6/10 | Integrated BioPharma reported a severe Q4 and FY2026 earnings miss, with Q4 revenue falling 31.0% YoY to $9.8M and a net | Sep 25, 2026 |
| CELZ | 8-K | mixed | 5/10 | Creative Medical Technology Holdings (CELZ) acquired an additional 4 million shares of BioDefense, Inc. from affiliate C | Sep 25, 2026 |